AstraZeneca and Bristol-Myers Squibb complete expansion of diabetes alliance
9 August 2012 | By AstraZeneca
AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals...
List view / Grid view
9 August 2012 | By AstraZeneca
AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals...
8 August 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced the successful completion of the tender offer...
10 July 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb announced on Friday, June 29, 2012, its intent to acquire Amylin...
30 June 2012 | By AstraZeneca
Bristol-Myers Squibb to acquire Amylin...
23 March 2012 | By Amylin Pharmaceuticals, Inc.
Patients in pivotal study achieved better glycemic control overall and after meals...
17 February 2012 | By Eli Lilly and Company
Patients in pivotal study achieved better glycemic control without weight gain...
19 October 2011 | By Eli Lilly and Company
FDA has approved a new use for BYETTA® (exenatide) injection....
12 September 2011 | By Eli Lilly and Company
Results presented at EASD 2011...
5 August 2011 | By Takeda Pharmaceutical Company Limited
Collaboration will explore potential of other assets to address obesity epidemic...
21 June 2011 | By Eli Lilly and Company
Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to BYDUREON™...
17 May 2011 | By Amylin Pharmaceuticals
Complaint alleges anti-competitive activity and breach of strategic alliance agreements...